D-serine in Schizophrenia

NCT ID: NCT03702933

Last Updated: 2018-10-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

starch

D-serine

Intervention Type DIETARY_SUPPLEMENT

dosage

High Dose

3.5 g/d D-serine adjuvant treatment

D-serine

Intervention Type DIETARY_SUPPLEMENT

dosage

Low Dose

2.1 g/d D-serine adjuvant treatment

D-serine

Intervention Type DIETARY_SUPPLEMENT

dosage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D-serine

dosage

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-5 Schizophrenia criteria, able and willing to give informed consent, and comply to study procedure, adequate contraception, post-menopausal or abstinent, PANSS Total Score equal or greater than 70, score of 4 or greater on two psychotic items

Exclusion Criteria

* clinically significant, uncontrollable or unstable medical condition, mental retardation or severe organic brain syndrome, significant risk of suicide or violent behavior
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Herzog Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Heresco-Levi Uriel

Professor of Psychiatry

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Uriel Heresco-Levy, MD

Role: PRINCIPAL_INVESTIGATOR

Herzog Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herzog Hospital

Jerusalem, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

andrea durrant, PhD

Role: CONTACT

972527181489

Uriel Heresco-Levy, MD

Role: CONTACT

97225316906

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andrea Durrant, PhD

Role: primary

972527181489

Uriel Heresco-Levy, MD

Role: backup

97225316906

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HerzogHospital

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

D-serine for the Schizophrenia Prodrome
NCT00826202 COMPLETED PHASE2
D-serine Augmentation of Neuroplasticity
NCT03711500 COMPLETED PHASE1/PHASE2
Vitamin D for Schizophrenia
NCT01759485 COMPLETED NA
Oxygen Therapy in Schizophrenia
NCT00525863 UNKNOWN PHASE3
Trial of D-Cycloserine in Schizophrenia
NCT00000371 COMPLETED PHASE3